Amgen has claimed victory in a lawsuit this week that will secure its patent for Otezla, a blockbuster med.
Earlier this week, the U.S. District Court for the District of New Jersey decided that Sandoz and Zydus Pharmaceuticals had infringed on Amgen’s patent for the drug.
The medication, which is used to treat a range of inflammatory conditions including psoriasis, psoriatic arthritis and oral ulcers linked with Behçet’s disease, was acquired by Amgen in 2014 for $13.4 billion in cash. The now blockbuster drug generated $2.2 billion in sales in 2020.
Prior to the ruling, both Sandoz and Zydus admitted that their generic versions of Otezla infringed on several patents for the drug. The latest ruling now protects prohibits Sandoz and Zydus from making, using, selling, importing, or marketing any of the generic versions of Otezla until February 2028.
